Very a short while ago, preliminary results from a third trial comparing ibrutinib compared to observation were presented.one hundred and five Sufferers obtaining ibrutinib experienced an extended event-cost-free survival, but no Over-all survival benefit, Even though the results were being nonetheless immature. Moreover, Despite the fact that seri